Innoblative Designs

Executive Summary

Innoblative Designs is a privately held medical device company headquartered in San Francisco, focused on addressing unmet clinical needs in breast cancer and other soft tissue diseases. The company's lead product, the SIRA® RFA Electrosurgical Device, has received Breakthrough Device Designation from the FDA, indicating its potential to provide more effective treatment options compared to existing standards of care. This designation expedites the development and review process, positioning Innoblative for accelerated regulatory pathways. Although the company is still in a pre-commercial stage with limited public information on funding or valuation, the breakthrough designation underscores the innovation and clinical significance of its technology. The SIRA device aims to improve outcomes in soft tissue ablation, potentially reducing recurrence rates and enhancing patient quality of life. With a focus on oncology, Innoblative targets a large and growing market, as breast cancer remains a leading cause of cancer-related deaths globally. The company's future success hinges on successful clinical trials, regulatory clearance, and eventual commercial adoption.

Upcoming Catalysts (preview)

• Q3 2026Release of pivotal clinical trial data for SIRA RFA device60% success
• Q4 2026FDA premarket approval (PMA) submission or 510(k) clearance decision50% success
• TBDStrategic partnership or licensing agreement with a larger medical device or pharmaceutical company40% success